<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111678</url>
  </required_header>
  <id_info>
    <org_study_id>1/2021</org_study_id>
    <nct_id>NCT05111678</nct_id>
  </id_info>
  <brief_title>Neurological Symptoms and Findings in Individuals Exposed to Indoor Air Pollutants</brief_title>
  <official_title>Neurological Symptoms and Findings in Individuals Exposed to Indoor Air Pollutants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate neurological findings with TSPO-PET and MRI in patients who have been exposed to&#xD;
      indoor air pollutants and have potentially neurological symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Health problems related to indoor air pollutants have been studied for several decades but&#xD;
      there is still not sufficient scientific evidence to prove the association between many of&#xD;
      the described symptoms and exposure to mold and other air pollutants.&#xD;
&#xD;
      This research aims on studying the activation of microglia and inflammation in the brains of&#xD;
      individuals exposed to indoor air pollutants having neurological symptoms with MRI and&#xD;
      TSPO-PET imaging, questionnaires and biomarkers and compare the findings to individuals&#xD;
      having neurological conditions without exposure to indoor air pollutants as well as healthy&#xD;
      controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>[11C]PK11195 binding in the brain</measure>
    <time_frame>Baseline</time_frame>
    <description>Change in microglial activity in the brains of the individuals in different study groups as measured by [11C]PK11195 PET imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DTI-MRI metrics</measure>
    <time_frame>Baseline</time_frame>
    <description>To evaluate the microstructural damage of the brain between individuals in different groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results from questionnaires</measure>
    <time_frame>Baseline</time_frame>
    <description>Questionnaires about quality of life compared between the indoor air pollutant and neurological symptoms groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>Biomarkers measured from blood to assess the possible inflammatory state of individuals in different study groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurography measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Done additionally if clinical studies indicate necessary, to assess the state of peripheral nerves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electromyography measures</measure>
    <time_frame>Baseline</time_frame>
    <description>Done additionally if clinical studies indicate necessary, rating each examined muscle as normal/myopathic/neuropathic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal fluid biomarkers</measure>
    <time_frame>Baseline</time_frame>
    <description>Biomarkers measured from cerebrospinal fluid to assess the possible inflammatory state of individuals in different study groups</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Exposure to Polluted Air</condition>
  <arm_group>
    <arm_group_label>Indoor air pollutant groups</arm_group_label>
    <description>50 patients that have been exposed to indoor air pollutants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neurological symptoms groups</arm_group_label>
    <description>50 patients with neurological symptoms possibly due to adverse external exposure without any exposure to indoor air pollutants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>25 healthy age- and gender-matched controls</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and cerebrospinal fluid&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will recruit 50 patients who have been exposed to indoor air pollutants and have&#xD;
        possibly neurological symptoms. For comparison the study will recruit also 50 patients with&#xD;
        neurological symptoms due to a possible adverse external exposure and who have not been&#xD;
        exposed to indoor air pollutants. Additionally, 25 healthy controls will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All:&#xD;
&#xD;
          -  Signing the informed consent form&#xD;
&#xD;
          -  Adults over 18 years of age&#xD;
&#xD;
        Indoor air pollutant groups:&#xD;
&#xD;
          -  Exposed to indoor air pollutants&#xD;
&#xD;
          -  Neurological symptoms&#xD;
&#xD;
        Neurological symptoms groups:&#xD;
&#xD;
          -  Neurological symptoms possibly due to adverse external exposure&#xD;
&#xD;
        Healthy controls:&#xD;
&#xD;
          -  Reported healthy person&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All:&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Corticosteroid treatment within 4 weeks of imaging&#xD;
&#xD;
          -  Patients with claustrophobia, or a history of moderate to severe anxiety disorder or&#xD;
             panic attacks (which could potentially lead to preterm termination of the imaging)&#xD;
&#xD;
          -  Contraindication to PET scan and MRI investigations&#xD;
&#xD;
          -  Exposure to experimental radiation in the past 12 months such that radiodosimetry&#xD;
             limits would be exceeded by participating in this study.&#xD;
&#xD;
          -  Intolerance to previous PET scans; i.e. previous hypersensitivity reactions to any PET&#xD;
             ligand or imaging agent or failure to participate in and comply with previous PET&#xD;
             scans.&#xD;
&#xD;
        Neurological symptoms groups and healthy controls:&#xD;
&#xD;
          -  Exposure to indoor air pollutants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Airas, MD,Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Turku University Hospital, division of clinical neurosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Turku PET Centre</name>
      <address>
        <city>Turku</city>
        <state>Finland Proper</state>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Airas, MD,Professor</last_name>
      <phone>023130000</phone>
      <email>laura.airas@utu.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

